- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor
- Interventions
- Etigilimab, Nivolumab
- Drug
- Lead sponsor
- Mereo BioPharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Greenbrae, California • Los Angeles, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–44
of 44
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- Interventions
- Demcizumab, Pembrolizumab
- Drug
- Lead sponsor
- OncoMed Pharmaceuticals, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Ann Arbor, Michigan • New York, New York + 2 more
- Conditions
- Solid Tumors
- Interventions
- OMP-59R5
- Drug
- Lead sponsor
- OncoMed Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • San Antonio, Texas
- Conditions
- Locally Advanced Malignant Neoplasm, Metastatic Cancer
- Interventions
- OMP-336B11
- Drug
- Lead sponsor
- OncoMed Pharmaceuticals, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Pancreatic Cancer
- Interventions
- Demcizumab, Abraxane®, gemcitabine, Placebo
- Drug
- Lead sponsor
- OncoMed Pharmaceuticals, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 22
- States / cities
- Gilbert, Arizona • Burbank, California • Duarte, California + 19 more
- Conditions
- Covid19
- Interventions
- Alvelestat, Placebo
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Relapsed or Refractory Lymphoid Malignancies
- Interventions
- OMP-52M51
- Drug
- Lead sponsor
- OncoMed Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 10
- States / cities
- La Jolla, California • Aurora, Colorado • Gainesville, Florida + 5 more
- Conditions
- Relapsed or Refractory Solid Tumors
- Interventions
- OMP-52M51
- Drug
- Lead sponsor
- OncoMed Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 6
- States / cities
- San Francisco, California • Aurora, Colorado • Detroit, Michigan + 2 more
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Setrusumab, Placebo
- Biological · Other
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 5 Years to 25 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 20 more
- Conditions
- Primary Peritoneal Carcinoma
- Interventions
- Demcizumab, Taxol
- Drug
- Lead sponsor
- OncoMed Pharmaceuticals, Inc.
- Industry
- Eligibility
- 21 Years to 90 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 3
- States / cities
- Oklahoma City, Oklahoma • Philadelphia, Pennsylvania • Houston, Texas
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- BCT197, Placebo
- Drug
- Lead sponsor
- Mereo BioPharma
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Michigan City, Indiana • Baltimore, Maryland • Milwaukee, Wisconsin
- Conditions
- Advanced Relapsed Tumors, Refractory Solid Tumors
- Interventions
- OMP-131R10, FOLFIRI
- Drug
- Lead sponsor
- OncoMed Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 7
- States / cities
- San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 4 more
- Conditions
- Acute Kidney Injury
- Interventions
- BCT197 Part A, Placebo, BCT197 Part B
- Drug
- Lead sponsor
- Mereo BioPharma
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 6
- States / cities
- Orange, California • Saginaw, Michigan • Lincoln, Nebraska + 3 more
- Conditions
- Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III, Osteogenesis Imperfecta Type IV
- Interventions
- setrusumab, Calcium, Vitamin D, zoledronic acid (optional)
- Drug · Dietary Supplement
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Jacksonville, Florida • Baltimore, Maryland + 9 more
- Conditions
- Locally Advanced Cancer, Metastatic Cancer
- Interventions
- OMP-313M32, Nivolumab
- Drug
- Lead sponsor
- OncoMed Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Durham, North Carolina • Oklahoma City, Oklahoma + 2 more
- Conditions
- Alpha 1-Antitrypsin Deficiency, Emphysema, COPD
- Interventions
- Placebo Oral Tablet, Alvelestat oral tablet - dose 1, Alvelestat oral tablet - dose 2
- Drug
- Lead sponsor
- Mereo BioPharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 1 more
- Conditions
- Pancreatic Cancer, Stage IV Pancreatic Cancer
- Interventions
- Vantictumab, Nab-Paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- OncoMed Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 2 more
- Conditions
- Osteopenia, Osteoporosis
- Interventions
- BPS804 20mg/Kg, Placebo to 20mg/Kg BPS804
- Drug
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 45 Years to 85 Years · Female only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 5
- States / cities
- Anaheim, California • Miami, Florida • Berlin, New Jersey + 1 more
- Conditions
- Hypogonadotropic Hypogonadism
- Interventions
- BGS649, Placebo
- Drug
- Lead sponsor
- Mereo BioPharma
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 45 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Vantictumab combined with paclitaxel
- Drug
- Lead sponsor
- OncoMed Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Aurora, Colorado • Dallas, Texas + 1 more